Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial

Pei-li Wang; Lei Zhang; Shao-li Wang; Qiao-ning Yang; Zhu-ye Gao; Jian-peng Du; Da-wu Zhang; Chang-geng Fu; Feng Gu; Hao Xu; Li-zhi Li; Cheng-long Wang; Da-zhuo Shi

doi:10.1007/s11655-016-2608-9

Your Location：

Home >

Browse articles >

Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial

Updated：2021-08-27

- Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial
- Chinese Journal of Integrative Medicine Vol. 23, Issue 10, Pages: 740-746(2017)
- Affiliations：
  
  1. Institute of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Department of Gastroenterology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by the Eleventh Five-Year Plan for Science and Technology Research of China (No. 2006BA104A01), and National Program on Key Basic Research Project of China (No. 2015CB554402)
- DOI：10.1007/s11655-016-2608-9
  CLC：
- Published：2017，
  
  Published Online：24 October 2016，
Scan for full text
Wang, Pl., Zhang, L., Wang, Sl. et al. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial., Chin. J. Integr. Med. 23, 740–746 (2017). https://doi.org/10.1007/s11655-016-2608-9

Pei-li Wang, Lei Zhang, Shao-li Wang, et al. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial. [J]. Chinese Journal of Integrative Medicine 23(10):740-746(2017)
Wang, Pl., Zhang, L., Wang, Sl. et al. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial., Chin. J. Integr. Med. 23, 740–746 (2017). https://doi.org/10.1007/s11655-016-2608-9 DOI：

Pei-li Wang, Lei Zhang, Shao-li Wang, et al. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial. [J]. Chinese Journal of Integrative Medicine 23(10):740-746(2017) DOI： 10.1007/s11655-016-2608-9.

摘要

To evaluate the prognosis effect of Chinese herbal medicines (CHMs) for benefiting qi and activating blood circulation adjunctive to conventional treatment in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). A total of 702 patients with ACS who underwent PCI were enrolled and randomly assigned to receive conventional treatment plus CHMs for benefiting qi and activating blood circulation (treatment group

351 cases) or conventional treatment alone (control group

351 cases) for 6 months. Six months later

all patients received conventional treatment alone. Follow-ups were scheduled at 6th

12th

18th

24th month after enrollment in April 2008

and the final follow-up visit was during September 2011 and November 2011. The primary endpoint was the composite of cardiac death

nonfatal myocardial infarction or revascularization (PCI or coronary artery bypass grafting); and the secondary endpoint was the composite of re-admission for ACS

congestive heart failure

nonfatal stroke or other thrombus events. A total of 621 (88.59%) patients completed 35.4±3.8 months follow-up

while 80 (11.41%) patients withdrew from the trial (41 in the treatment group and 39 in the control group). The incidence of primary endpoint was 5.7% (20 patients) in the treatment group versus 10.86% (38 patients) in the control group [relative risk (RR): 0.53; 95% confidence interval (CI): 0.30

0.88; P=0.013; absolute risk reduction (ARR):–0.052

95% CI: –0.06

0.01]. The incidence of secondary endpoint was 5.98% (21 patients) in the treatment group versus 10.28% (36 patients) in control group (RR: 0.58

95% CI: 0.33

0.97

P=0.037; ARR: –0.043

95% CI: 0.06

0.01). Most of the primary and secondary endpoints were occurred in 18 months (84.50% in the treatment group versus 78.10% in the control group). CHMs for benefiting qi and activating blood circulation adjunctive to conventional treatment improved clinical outcomes for patients with ACS after PCI in long-term follow-up.

Abstract

351 cases) or conventional treatment alone (control group

351 cases) for 6 months. Six months later

all patients received conventional treatment alone. Follow-ups were scheduled at 6th

12th

18th

24th month after enrollment in April 2008

and the final follow-up visit was during September 2011 and November 2011. The primary endpoint was the composite of cardiac death

nonfatal myocardial infarction or revascularization (PCI or coronary artery bypass grafting); and the secondary endpoint was the composite of re-admission for ACS

congestive heart failure

nonfatal stroke or other thrombus events. A total of 621 (88.59%) patients completed 35.4±3.8 months follow-up

0.88; P=0.013; absolute risk reduction (ARR):–0.052

95% CI: –0.06

0.01]. The incidence of secondary endpoint was 5.98% (21 patients) in the treatment group versus 10.28% (36 patients) in control group (RR: 0.58

95% CI: 0.33

0.97

P=0.037; ARR: –0.043

95% CI: 0.06

关键词

long-term follow-upChinese Medicinebenefit qi and activate blood circulationacute coronary syndromePercutaneous Coronary Intervention

Keywords

long-term follow-upChinese Medicinebenefit qi and activate blood circulationacute coronary syndromePercutaneous Coronary Intervention

references

Liu H, Wang YW. Progress on myocardial revascularization for coronary artery diseases. J Tongji Univ (Med Sci) 2003;24:330–333.

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003;361:13–20.

Li YQ, Jin M, Qiu SL, Zhu TG, Bian H, Wang CL, et al. Effect of Chinese herbal medicine for benefiting qi and nourishing yin to promote blood circulation on ventricular wall motion of AMI patients after revascularization. J Chin Integr Med (Chin) 2009;29:300–304.

Zhang DW, Wang CL, Wang PL, Shi DZ. Evolution of TCM syndrome elements in acute coronary syndrome treated with Chinese herb for nourishing qi and activating blood circulation after percutaneous coronary intervention. Chin J Integr Med Cardio/Cerebrovasc Dis (Chin) 2013;11:385–388.

Wang PL, Wang CL, Wang SL, Shi DZ. Quality of life of Chinese herbal medicine for nourishing qi and removing blood stasis on acute coronary syndrome patients after percutaneous coronary intervention. Glob Tradit Chin Med (Chin) 2012;5:881–885.

Wang SL, Wang CL, Wang PL, Xu H, Liu HY, Du JP, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C trial): an open-label randomized controlled multi-center study. Evid Based Complement Alternat Med 2013;2013:741518.

Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guideline for diagnosis and treatment of patients with unstable angina and non-ST-segment elevation myocardial infarction. Chin J Cardiol (Chin) 2007;35:295–304.

American College of Cardiology/American Heart Association. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. JACC 2008;51:210–247.

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997;277:925–926.

Ho HH, Pong V, Siu CW, Jim MH, Miu R, Yiu KH, et al. Longterm clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese patients. Clin Cardiol 2010;33:e22-E29.

Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, et al. Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114–1120.

Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Bøttcher M, et al. Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Interv 2008;1:176–184.

Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation 2011;124:1283–1287.

Burzotta F, Parma A, Pristipino C, Manzoli A, Belloni F, Sardella G, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the optimist study. Eur Heart J 2008;29:3011–3021.

FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ ucm203888.htm#AIHP. Accessed 25 April 2014.

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374–1382.

Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, doubleblind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drugeluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035–1041.

Li GK, Fan JS, Li HM. The protective effect of panax quinquefolium on ventricular remodeling of rats. Chin J Gerontol (Chin) 2011;31:4634–4636.

Xue M, Yang L, Shi DZ, Radauer C, Breiteneder H, Ma Y. Qualitative analysis of Xinyue Capsules by highperformance liquid chromatography: preliminary evaluation of drug quality in a Sino-Austrian joint study. Chin J Integr Med 2015;21:772–777.

Chen XP, Li W, Xiao XF, Zhang LL, Liu CX. Phytochemical and pharmacological studies on Radix Angelica sinensis. Chin J Nat Med 2013;11:577–587.

Qiao ZY, Mang JW, Liu HJ. Effect of Ligusticum wallichii aqueous extract on oxidative injury and immunity activity in myocardial ischemic reperfusion rats. Int J Mol Sci 2011;12:1991–2006.

Wang BJ, Zhang QX, Zhang L, Liu JG, Shi DZ. Effect of qisupplementing blood-quickening medicinal combined with dual antiplatelet therapy on the thrombosis in acute myocardial infarction rats. J Tradit Chin Med (Chin) 2013;54:1225–1229.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention

Combined therapy with Chinese medicine and percutaneous transradial coronary intervention for a centenarian patient with acute myocardial infarction

Effect of Danlou Tablet (丹蒌片) on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial

Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial

Related Author

No data

Related Institution

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University

Department of Cardiology, Peking University First Hospital

Xiyuan Hospital, China Academy of Chinese Medical Sciences

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University

Heart Center, Guangdong Provincial Hospital of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰